Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies (Q34803735)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Enterobacteriaceae

0 references

Drosos E. Karageorgopoulos

object named as

Drosos E Karageorgopoulos

2

0 references

Theodoros Kelesidis

object named as

Theodoros Kelesidis

1

0 references

Matthew E. Falagas

4

object named as

Matthew E Falagas

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Iosif Kelesidis

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

1 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

895-904

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Tigecycline: what is it, and where should it be used?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Glycylcyclines: third-generation tetracycline antibiotics

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Tigecycline: in-vitro performance as a predictor of clinical efficacy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activities of tigecycline against clinical isolates from Shanghai, China

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Extended-spectrum beta-lactamases and the permeability barrier.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Validation and reproducibility assessment of tigecycline MIC determinations by Etest

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Rapid development of Acinetobacter baumannii resistance to tigecycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN311

21 January 2018

Identifiers

10.1093/JAC/DKN311

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34803735&oldid=1953323454"